Aging is driven by interconnected biological processes, collectively known as the hallmarks of aging, that include genomic instability, cellular senescence and mitochondrial dysfunction. Although genetic and experimental studies have implicated thousands of genes in aging and longevity, translating this knowledge into therapies remains difficult because no aging pathway acts in isolation. Meanwhile, thousands of approved or clinically tested drugs already exist, many with known targets, pharmacology and safety information; some of these compounds could potentially be repurposed to modulate specific longevity-related processes. Such repurposing requires researchers to distinguish drugs that might promote healthy aging from those that could inadvertently reinforce age-related decline. We develop a systems-level framework that integrates genetic, network and transcriptional information to identify candidate longevity interventions.
